AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...

AbbVie (ABBV) shares snapped eight consecutive sessions of losses as the stock closed up XYZ% at $XYZ. The North ...

Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review. The stock rose 11% ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...

The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...

Aldeyra (ALDX) announced FDA acceptance of its resubmitted market application for reproxalap and an expansion of its option agreement with AbbVie (ABBV). Read more here.

Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...

The trial of the PanEcho software, presented at the American Heart Association (AHA) congress in Chicago, suggests that it ...